Vir Biotechnology president and CEO George Scangos explains why many companies struggle to build a sustainable business model around fighting infectious diseases, particularly when it comes to developing antibiotics. However, he adds, certain therapies for viral diseases are currently more financially viable. Dr. Scangos explores why Vir decided to go “all-in” on infectious diseases, how they built a company around that mission, and how the arrival of COVID-19 impacted the young company’s trajectory.
Related
Annie Hockey,
Column
Reimagining Fintech [Entire Talk]
The banking industry poses complex regulatory challenges for fintech entrepreneurs — but the space is ripe for innovation.
Annie Hockey,
Column
Reimagining Fintech [Entire Talk]
The banking industry poses complex regulatory challenges for fintech entrepreneurs — but the space is ripe for innovation.
Elise Densborn,
Splendid Spoon
From Customer to Co-CEO [Entire Talk]
Passion for a brand or industry can be an incredible starting point for gaining entrepreneurial experience.
Elise Densborn,
Splendid Spoon
From Customer to Co-CEO [Entire Talk]
Passion for a brand or industry can be an incredible starting point for gaining entrepreneurial experience.
Dante Disparte,
Circle
Ethical Crypto Innovation [Entire Talk]
To build a better crypto industry, start with ethics.
Dante Disparte,
Circle
Ethical Crypto Innovation [Entire Talk]
To build a better crypto industry, start with ethics.
